MAIA Biotechnology grants Luput 33,536 stock options
The options vest 100% on September 30, 2026, are exercisable beginning that day, and expire on September 30, 2036.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MAIA Biotechnology, Inc. director Cristian Luput received 33,536 stock options under the company’s 2021 Equity Incentive Plan on September 30, 2026, with an exercise price of $1.18 per share. The options represent the right to buy common stock, and the reported position after the grant is 33,536 options.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options F1 | 33,536 | $0.00 | $0.00 |
Footnotes (1)
- F1. The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Key Figures
Key Terms
vesting financial
exercisable financial
exercise price financial
2021 Equity Incentive Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many MAIA options did director Cristian Luput receive?
When do Cristian Luput’s MAIA options vest and expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.